A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion
Phase: Phase I-II clinical trials
Principal Investigator: Dott.ssa Proto Claudia
Main Facility: Oncologia Medica Toraco-Polmonare
Drug: BMS-986504
Pathologies: Lung cancer
ClinicalTrials.gov: Read the details about clinical trials
This is a global Phase 2/3 clinical trial in patients with metastatic non-small cell lung cancer (NSCLC) harboring a homozygous MTAP deletion. The study is designed to evaluate the safety and efficacy of a new investigational agent, BMS-986504, administered in combination with pembrolizumab and chemotherapy, compared with the current standard treatment consisting of pembrolizumab plus chemotherapy.
Participants will be randomly assigned (1:1 randomization) to one of two treatment arms to compare the investigational treatment with the standard of care.
Arm A (Investigational Arm): BMS-986504 administered in combination with pembrolizumab and chemotherapy. BMS-986504 is a novel investigational agent designed to selectively target tumor cells harboring MTAP deletion, with the aim of enhancing the effectiveness of treatment.
Arm B (Control Arm): Placebo administered in combination with pembrolizumab and chemotherapy, which represents the current standard first-line treatment for this patient population.
The study is intended for patients with metastatic NSCLC who have not previously received systemic therapy for metastatic disease and whose tumors harbor a homozygous MTAP deletion. The primary objective of the study is to determine whether the addition of BMS-986504 to standard therapy can improve disease control and survival compared with standard therapy alone.
Last update: 16/07/2026